Generic Name and Formulations:
Dextranomer microspheres 50mg/mL viscous gel in stabilized hyaluronic acid 15mg/mL carrier gel; implant for submucosal inj.
Bausch Health Companies Inc.
Indications for DEFLUX:
Vesicoureteral reflux (VUR) grades II–IV in children.
<1yr: not recommended. ≥1yr: see literature. Must use Deflux metal needle for administration. Inject submucosally in urinary bladder near the ureteral orifice.
Non-functional kidney. Hutch diverticulum. Ureterocele. Active voiding dysfunction. Ongoing UTI.
Do not inject intravascularly. Must be administered by qualified surgeon experienced in the use of cystoscope and trained in subureteric injection procedures. Use of >6mL (3mL at each ureteral orifice) at same treatment session: not recommended. Treatment of duplex systems has not been studied. Ureters with grossly dilated orifices. Infection and bleeding risks associated with cystoscopic procedure.
UTI, ureteral dilatation, nausea, vomiting, abdominal pain.
Single-use syringe (1mL)—1
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL